董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Samraat S. Raha | 男 | Chief Executive Officer and Director and President | 54 | 568.67万美元 | 16.20 | 2026-04-14 |
| Daniel M. Skovronsky | 男 | Director | 52 | 32.85万美元 | 13.58 | 2026-04-14 |
| Colleen F. Reitan | 女 | Director | 66 | 33.85万美元 | 9.23 | 2026-04-14 |
| Lee N. Newcomer | 男 | Director | 73 | 34.30万美元 | 13.21 | 2026-04-14 |
| Rashmi Kumar | 女 | Director | 57 | 32.85万美元 | 12.72 | 2026-04-14 |
| Mark S. Davis | 男 | Director | 63 | 21.19万美元 | 4.70 | 2026-04-14 |
| Heiner Dreismann | 男 | Director | 73 | 33.85万美元 | 17.14 | 2026-04-14 |
| S. Louise Phanstiel | 女 | Chair of the Board and Director | 67 | 45.10万美元 | 31.51 | 2026-04-14 |
| Paul M. Bisaro | 男 | Director | 65 | 33.42万美元 | 8.99 | 2026-04-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Verratti | 男 | Chief Operating Officer | 58 | 314.53万美元 | 未持股 | 2026-04-14 |
| Samraat S. Raha | 男 | Chief Executive Officer and Director and President | 54 | 568.67万美元 | 16.20 | 2026-04-14 |
| Ben R. Wheeler | 男 | Chief Financial Officer | 43 | 150.79万美元 | 2.13 | 2026-04-14 |
| Jennifer Fox | 女 | Chief Legal Officer | 53 | 未披露 | 未持股 | 2026-04-14 |
| Dale Muzzey | 男 | Chief Scientific Officer | 46 | 186.29万美元 | 8.71 | 2026-04-14 |
| Brian Donnelly | 男 | Chief Commercial Officer | 43 | 600.01万美元 | 11.00 | 2026-04-14 |
| Shereen Solaiman | 女 | Chief People Officer | 53 | 未披露 | 未持股 | 2026-04-14 |
董事简历
中英对照 | 中文 | 英文- Samraat S. Raha
-
Samraat S. Raha自2018年4月起担任安捷伦高级副总裁兼诊断与基因组学总裁。从2017年5月至2018年4月，Raha先生担任战略与企业发展高级副总裁。 2013年6月至2017年1月，他担任Illumina公司全球营销副总裁，并于2008年至2012年担任Life Technologies Assays / NextGen qPCR for Life Technologies，Inc的副总裁兼总经理。
Samraat S. Raha has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Diagnostics and Genomics Group since April 2018. From May 2017 to April 2018, Mr. Raha served as Agilent Technologies, Inc. Senior Vice President, Strategy and Corporate Development. From June 2013 to January 2017 he served as Vice President, Global Marketing for Illumina, Inc. and from 2008 to 2012 he served as Vice President and General Manager, Genomic Assays / NextGen qPCR for Life Technologies, Inc. Mr. Raha graduated from the University of California, Berkeley, with a degree in molecular and cell biology and received his MBA from Santa Clara University. - Samraat S. Raha自2018年4月起担任安捷伦高级副总裁兼诊断与基因组学总裁。从2017年5月至2018年4月，Raha先生担任战略与企业发展高级副总裁。 2013年6月至2017年1月，他担任Illumina公司全球营销副总裁，并于2008年至2012年担任Life Technologies Assays / NextGen qPCR for Life Technologies，Inc的副总裁兼总经理。
- Samraat S. Raha has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Diagnostics and Genomics Group since April 2018. From May 2017 to April 2018, Mr. Raha served as Agilent Technologies, Inc. Senior Vice President, Strategy and Corporate Development. From June 2013 to January 2017 he served as Vice President, Global Marketing for Illumina, Inc. and from 2008 to 2012 he served as Vice President and General Manager, Genomic Assays / NextGen qPCR for Life Technologies, Inc. Mr. Raha graduated from the University of California, Berkeley, with a degree in molecular and cell biology and received his MBA from Santa Clara University.
- Daniel M. Skovronsky
-
Daniel M. Skovronsky，科学与技术高级副总裁兼礼来研究实验室总裁，于2018年6月生效。2010年加入公司之前，Skovronsky博士是Avid Radiopharmaceutical公司的首席执行官和创始人。
Daniel M. Skovronsky has served as a director of Myriad since July 2020. Dr. Skovronsky currently serves as President of Lilly Research Laboratories, President of Lilly Immunology, and Chief Scientific Officer at Eli Lilly and Company. Previously, he served as Chief Executive Officer of Avid Radiopharmaceuticals Inc., a company he founded in 2004. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania, his Ph.D. in neuroscience from the University of Pennsylvania, and a B.S. in molecular biophysics and biochemistry from Yale University. - Daniel M. Skovronsky，科学与技术高级副总裁兼礼来研究实验室总裁，于2018年6月生效。2010年加入公司之前，Skovronsky博士是Avid Radiopharmaceutical公司的首席执行官和创始人。
- Daniel M. Skovronsky has served as a director of Myriad since July 2020. Dr. Skovronsky currently serves as President of Lilly Research Laboratories, President of Lilly Immunology, and Chief Scientific Officer at Eli Lilly and Company. Previously, he served as Chief Executive Officer of Avid Radiopharmaceuticals Inc., a company he founded in 2004. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania, his Ph.D. in neuroscience from the University of Pennsylvania, and a B.S. in molecular biophysics and biochemistry from Yale University.
- Colleen F. Reitan
-
ColleenF.Reitan于2019年9月被任命为董事会成员。Reitan女士曾在Health Care Services Corporation HCSC担任多个高级领导职位，包括最近担任执行Vice President和计划运营总裁以及首席运营官。在HCSC工作之前，Reitan女士在Blue Cross和Blue Shield of Minnesota担任过许多高级管理职位，包括首席运营官。总的来说，Reitan女士在管理式护理行业拥有超过35年的经验。Reitan女士拥有明尼苏达州立大学曼卡托分校（Minnesota State University at Mankato）的学士学位和明尼苏达大学双子城分校（University of Minnesota-Twin Cities）的医疗保健管理硕士学位。她目前在AlnylamPharmaceuticals，Inc.董事会任职。
Colleen F. Reitan has served as director of Myriad since September 2019. Ms. Reitan currently serves on the board of directors of Alnylam Pharmaceuticals, Inc. Previously, she held numerous senior leadership positions at Health Care Services Corporation (HCSC), including most recently as the Executive Vice President and President of Plan Operations, as well as the Chief Operating Officer. Prior to her time at HCSC, Ms. Reitan held several senior management positions at Blue Cross and Blue Shield of Minnesota, including President and Chief Operating Officer. In aggregate, Ms. Reitan has over 35 years of experience in the managed care industry. She holds a B.A. from Minnesota State University at Mankato and an M.S. in Health Care Administration from the University of Minnesota Twin Cities. - ColleenF.Reitan于2019年9月被任命为董事会成员。Reitan女士曾在Health Care Services Corporation HCSC担任多个高级领导职位，包括最近担任执行Vice President和计划运营总裁以及首席运营官。在HCSC工作之前，Reitan女士在Blue Cross和Blue Shield of Minnesota担任过许多高级管理职位，包括首席运营官。总的来说，Reitan女士在管理式护理行业拥有超过35年的经验。Reitan女士拥有明尼苏达州立大学曼卡托分校（Minnesota State University at Mankato）的学士学位和明尼苏达大学双子城分校（University of Minnesota-Twin Cities）的医疗保健管理硕士学位。她目前在AlnylamPharmaceuticals，Inc.董事会任职。
- Colleen F. Reitan has served as director of Myriad since September 2019. Ms. Reitan currently serves on the board of directors of Alnylam Pharmaceuticals, Inc. Previously, she held numerous senior leadership positions at Health Care Services Corporation (HCSC), including most recently as the Executive Vice President and President of Plan Operations, as well as the Chief Operating Officer. Prior to her time at HCSC, Ms. Reitan held several senior management positions at Blue Cross and Blue Shield of Minnesota, including President and Chief Operating Officer. In aggregate, Ms. Reitan has over 35 years of experience in the managed care industry. She holds a B.A. from Minnesota State University at Mankato and an M.S. in Health Care Administration from the University of Minnesota Twin Cities.
- Lee N. Newcomer
-
LeeN.Newcomer医学博士于2019年9月被任命为董事会成员。Newcomer博士目前管理着自己的咨询公司LeeN.Newcomer Consulting，LLC，此前曾在联合梦百合担任高级执行职务，包括肿瘤和遗传学高级副总裁、首席医疗官以及联合健康集团健康政策和战略高级副总裁。Newcomer博士还曾在Vivius，Inc.工作，该公司是一家面向消费者的健康计划公司，担任执行Vice President和首席医疗官。Newcomer博士在麦迪逊威斯康星大学（University of Wisconsin）获得梦百合管理硕士学位，在奥马哈的内布拉斯加大学（University of Nebraska）获得医学博士学位，在内布拉斯加州卫斯理大学（Nebraska Wesleyan University）获得工商管理硕士学位。Newcomer博士目前任职于Cellworks Group Inc.的董事会，这是一家私人精准医疗公司和Intervention Insights，这是一家基因组测试决策支持公司。他也曾任职Park Nicollet Health Systems公司（医院医疗保健系统，拥有大约1000名医生和400张床）的董事会10年，包括担任主席两年。
Lee N. Newcomer has served as a director of Myriad since September 2019. Dr. Newcomer currently manages his own consulting business, Lee N. Newcomer Consulting, LLC. He also currently serves on the board of directors of Coherus BioSciences, Inc., a public biopharmaceutical company, and Cellworks Group Inc., a private precision medicine company. Previously, he held several senior executive roles at United Healthcare Group, including Senior Vice President for Oncology and Genetics, Chief Medical Officer and Senior Vice President of Health Policy and Strategy. Dr. Newcomer also worked for Vivius, Inc., a consumer directed health plan, where he held the position of Executive Vice President and Chief Medical Officer. Dr. Newcomer's previous board service includes serving on the board of directors of Park Nicollet Health Systems, a hospital health care system with approximately 1,000 physicians and 400 beds, for ten years, including two years as Chairman. He received a B.S. from Nebraska Wesleyan University, a Master's Degree in Healthcare Administration & Management from the University of Wisconsin, Madison, and an M.D. from the University of Nebraska, Omaha. - LeeN.Newcomer医学博士于2019年9月被任命为董事会成员。Newcomer博士目前管理着自己的咨询公司LeeN.Newcomer Consulting，LLC，此前曾在联合梦百合担任高级执行职务，包括肿瘤和遗传学高级副总裁、首席医疗官以及联合健康集团健康政策和战略高级副总裁。Newcomer博士还曾在Vivius，Inc.工作，该公司是一家面向消费者的健康计划公司，担任执行Vice President和首席医疗官。Newcomer博士在麦迪逊威斯康星大学（University of Wisconsin）获得梦百合管理硕士学位，在奥马哈的内布拉斯加大学（University of Nebraska）获得医学博士学位，在内布拉斯加州卫斯理大学（Nebraska Wesleyan University）获得工商管理硕士学位。Newcomer博士目前任职于Cellworks Group Inc.的董事会，这是一家私人精准医疗公司和Intervention Insights，这是一家基因组测试决策支持公司。他也曾任职Park Nicollet Health Systems公司（医院医疗保健系统，拥有大约1000名医生和400张床）的董事会10年，包括担任主席两年。
- Lee N. Newcomer has served as a director of Myriad since September 2019. Dr. Newcomer currently manages his own consulting business, Lee N. Newcomer Consulting, LLC. He also currently serves on the board of directors of Coherus BioSciences, Inc., a public biopharmaceutical company, and Cellworks Group Inc., a private precision medicine company. Previously, he held several senior executive roles at United Healthcare Group, including Senior Vice President for Oncology and Genetics, Chief Medical Officer and Senior Vice President of Health Policy and Strategy. Dr. Newcomer also worked for Vivius, Inc., a consumer directed health plan, where he held the position of Executive Vice President and Chief Medical Officer. Dr. Newcomer's previous board service includes serving on the board of directors of Park Nicollet Health Systems, a hospital health care system with approximately 1,000 physicians and 400 beds, for ten years, including two years as Chairman. He received a B.S. from Nebraska Wesleyan University, a Master's Degree in Healthcare Administration & Management from the University of Wisconsin, Madison, and an M.D. from the University of Nebraska, Omaha.
- Rashmi Kumar
-
Rashmi Kumar自2020年9月起担任公司董事。目前，Kumar女士担任休斯敦惠普企业（Hewlett Packard Enterprise）的全球IT高级副总裁。她是一位经验丰富的技术领导者，在IT领导、梦百合、咨询服务、电力公用事业、金融服务、信息技术、媒体和娱乐以及钢铁行业有着广泛的经验。Kumar女士拥有超过25年的经验，其主要关注领域包括数字化转型，AI/ML，数据&分析，战略规划，企业架构和大规模业务流程转型。Rashmi Kumar&8217；s于2018年加入HPE，担任全球IT副总裁，专注于应用程序运营和支持，NGIT计划的构建和部署以及技术领导，以使HPE业务实现转型目标。Kumar女士曾担任许多财富50强公司的首席信息官和首席技术官，例如，McKesson，南加州爱迪生，丰田，HPE和塔塔钢铁。Rashmi Kumar在印度辛德里的比哈尔理工学院获得中国中冶工程学士学位。她还持有the University of California，Irvine；Paul Merage School of Business工商管理硕士学位。
Rashmi Kumar has served as a director of Myriad since September 2020. Ms. Kumar currently serves as Senior Vice President, Chief Information Officer with Medtronic plc, a position she has held since December 2022. Previously, she served as Senior Vice President and Chief Information Officer – Global IT with Hewlett Packard Enterprise (HPE) from January 2020 to November 2022, after joining HPE in 2018 as VP Global IT. Ms. Kumar is a seasoned technology leader with over 25 years of experience across various industries, including healthcare, cybersecurity, and financial services. Prior to HPE, Ms. Kumar held CIO and CTO leadership positions for several Fortune 50 companies, including McKesson, Southern California Edison, Toyota, HPE, and Tata Steel. Her primary areas of focus include digital transformation, AI/ML, data and analytics, and large scale business process transformations. Ms. Kumar earned a bachelor's degree in Metallurgical Engineering from the Bihar Institute of Technology in Sindri, India, and an MBA from the University of California, Irvine, Paul Merage School of Business. - Rashmi Kumar自2020年9月起担任公司董事。目前，Kumar女士担任休斯敦惠普企业（Hewlett Packard Enterprise）的全球IT高级副总裁。她是一位经验丰富的技术领导者，在IT领导、梦百合、咨询服务、电力公用事业、金融服务、信息技术、媒体和娱乐以及钢铁行业有着广泛的经验。Kumar女士拥有超过25年的经验，其主要关注领域包括数字化转型，AI/ML，数据&分析，战略规划，企业架构和大规模业务流程转型。Rashmi Kumar&8217；s于2018年加入HPE，担任全球IT副总裁，专注于应用程序运营和支持，NGIT计划的构建和部署以及技术领导，以使HPE业务实现转型目标。Kumar女士曾担任许多财富50强公司的首席信息官和首席技术官，例如，McKesson，南加州爱迪生，丰田，HPE和塔塔钢铁。Rashmi Kumar在印度辛德里的比哈尔理工学院获得中国中冶工程学士学位。她还持有the University of California，Irvine；Paul Merage School of Business工商管理硕士学位。
- Rashmi Kumar has served as a director of Myriad since September 2020. Ms. Kumar currently serves as Senior Vice President, Chief Information Officer with Medtronic plc, a position she has held since December 2022. Previously, she served as Senior Vice President and Chief Information Officer – Global IT with Hewlett Packard Enterprise (HPE) from January 2020 to November 2022, after joining HPE in 2018 as VP Global IT. Ms. Kumar is a seasoned technology leader with over 25 years of experience across various industries, including healthcare, cybersecurity, and financial services. Prior to HPE, Ms. Kumar held CIO and CTO leadership positions for several Fortune 50 companies, including McKesson, Southern California Edison, Toyota, HPE, and Tata Steel. Her primary areas of focus include digital transformation, AI/ML, data and analytics, and large scale business process transformations. Ms. Kumar earned a bachelor's degree in Metallurgical Engineering from the Bihar Institute of Technology in Sindri, India, and an MBA from the University of California, Irvine, Paul Merage School of Business.
- Mark S. Davis
-
Mark S. Davis自2024年12月10日起担任Myriad的董事。戴维斯先生目前担任Cross Country Consulting的高级关系和增长顾问，他自2024年10月以来一直担任该职位。此前，戴维斯先生在德勤会计师事务所（Deloitte & Touche LLP）享有卓越的职业生涯，任职时间从1985年到2024年9月。在德勤任职期间，他担任过多个高级领导职务，包括审计合伙人、德勤私营企业全国管理合伙人、长岛办事处管理合伙人。自2024年7月起，Davis先生一直在Yext, Inc.的董事会任职，并担任审计委员会成员。戴维斯先生还是阿德尔菲大学董事会成员，他在该大学的财务和投资委员会以及审计委员会任职。他以前的顾问参与包括担任纽约大学温思罗普医院顾问委员会成员和米尔河俱乐部董事会成员。他拥有阿德尔菲大学的学士学位，是一名注册会计师。
Mark S. Davis has served as a director of Myriad since December 10, 2024. Mr. Davis currently serves as Senior Relationship and Growth Advisor for Cross Country Consulting, a position he has held since October 2024. Previously, Mr. Davis enjoyed a distinguished career at Deloitte & Touche LLP, serving from 1985 until September 2024. During his tenure at Deloitte, he held several senior leadership roles, including Audit Partner, National Managing Partner of Deloitte Private Enterprises, and Managing Partner of the Long Island office. Since July 2024, Mr. Davis has served on the board of directors of Yext, Inc., where he is a member of the audit committee. Mr. Davis is also a member of the Board of Trustees at Adelphi University, where he serves on the finance and investment committee as well as the audit committee. His former advisory involvements include serving as a member of the advisory board of NYU Winthrop Hospital and on the Board of Governors of the Mill River Club. He holds a B.B.A. from Adelphi University and is a certified public accountant. - Mark S. Davis自2024年12月10日起担任Myriad的董事。戴维斯先生目前担任Cross Country Consulting的高级关系和增长顾问，他自2024年10月以来一直担任该职位。此前，戴维斯先生在德勤会计师事务所（Deloitte & Touche LLP）享有卓越的职业生涯，任职时间从1985年到2024年9月。在德勤任职期间，他担任过多个高级领导职务，包括审计合伙人、德勤私营企业全国管理合伙人、长岛办事处管理合伙人。自2024年7月起，Davis先生一直在Yext, Inc.的董事会任职，并担任审计委员会成员。戴维斯先生还是阿德尔菲大学董事会成员，他在该大学的财务和投资委员会以及审计委员会任职。他以前的顾问参与包括担任纽约大学温思罗普医院顾问委员会成员和米尔河俱乐部董事会成员。他拥有阿德尔菲大学的学士学位，是一名注册会计师。
- Mark S. Davis has served as a director of Myriad since December 10, 2024. Mr. Davis currently serves as Senior Relationship and Growth Advisor for Cross Country Consulting, a position he has held since October 2024. Previously, Mr. Davis enjoyed a distinguished career at Deloitte & Touche LLP, serving from 1985 until September 2024. During his tenure at Deloitte, he held several senior leadership roles, including Audit Partner, National Managing Partner of Deloitte Private Enterprises, and Managing Partner of the Long Island office. Since July 2024, Mr. Davis has served on the board of directors of Yext, Inc., where he is a member of the audit committee. Mr. Davis is also a member of the Board of Trustees at Adelphi University, where he serves on the finance and investment committee as well as the audit committee. His former advisory involvements include serving as a member of the advisory board of NYU Winthrop Hospital and on the Board of Governors of the Mill River Club. He holds a B.B.A. from Adelphi University and is a certified public accountant.
- Heiner Dreismann
-
Heiner Dreismann，他自2010年6月加入Myriad担任董事，1985年至2006年在罗氏集团拥有成功的职业生涯，曾担任多个高级职位，包括罗氏分子系统总裁兼首席执行官、罗氏诊断全球业务发展主管以及罗氏全球诊断执行委员会成员。从2006年到2009年，Dreismann博士担任Vectrant Technologies，Inc.的首席执行官，直到2013年是GeneNews Limited的临时首席执行官。过去五年，Dreismann博士曾在Med BioGene，Genenews Limited，Interpace诊断公司和Ignyta，Inc.的董事会任职。他以优异成绩获得德国明斯特大学Westfaelische Wilhelms University的生物学硕士学位和微生物学/分子生物学博士学位。
Heiner Dreismann has served as a director of Myriad since June 2010. Dr. Dreismann currently serves on the board of directors of Mainz Biomed N.V. and on a number of early stage private company boards in the biotechnology industry. Previously, Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006, where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann's previous public board service includes Talis Biomedical Corporation, Med BioGene, Inc., Genenews Limited, Interpace Diagnostics and Ignyta, Inc. He earned a M.S. degree in biology and his Ph.D. in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany. - Heiner Dreismann，他自2010年6月加入Myriad担任董事，1985年至2006年在罗氏集团拥有成功的职业生涯，曾担任多个高级职位，包括罗氏分子系统总裁兼首席执行官、罗氏诊断全球业务发展主管以及罗氏全球诊断执行委员会成员。从2006年到2009年，Dreismann博士担任Vectrant Technologies，Inc.的首席执行官，直到2013年是GeneNews Limited的临时首席执行官。过去五年，Dreismann博士曾在Med BioGene，Genenews Limited，Interpace诊断公司和Ignyta，Inc.的董事会任职。他以优异成绩获得德国明斯特大学Westfaelische Wilhelms University的生物学硕士学位和微生物学/分子生物学博士学位。
- Heiner Dreismann has served as a director of Myriad since June 2010. Dr. Dreismann currently serves on the board of directors of Mainz Biomed N.V. and on a number of early stage private company boards in the biotechnology industry. Previously, Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006, where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann's previous public board service includes Talis Biomedical Corporation, Med BioGene, Inc., Genenews Limited, Interpace Diagnostics and Ignyta, Inc. He earned a M.S. degree in biology and his Ph.D. in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.
- S. Louise Phanstiel
-
S. Louise Phanstiel，自2021年2月业务合并完成后担任董事会成员，并担任审计委员会主席。Phanstiel女士自2020年3月起担任Myriad Genetics, Inc.（纳斯达克：MYGN）或Myriad的董事会主席，并自2009年9月起担任Myriad的董事。Phanstiel女士此前曾于1996年至2007年在Elevance Health, Inc.（NYSE：ELV）（前身为Anthem，Inc.，在此之前为WellPoint，Inc.）担任多个高管职务。Phanstiel女士曾任特种产品总裁，其中包括行为健康服务；董事长办公室高级副总裁、参谋长和企业规划；WellPoint，Inc.所有子公司的首席会计官、财务总监兼首席财务官。此前，Phanstiel女士是国际服务公司普华永道会计师事务所（PricewaterhouseCoopers，LLP）的合伙人。Phanstiel女士的生命科学经验包括曾在上市公司Inveresk Research Group，Inc.和Verastem Oncology（纳斯达克：VSTM）担任董事会成员和审计委员会主席。
S. Louise Phanstiel has been a director of Myriad since September 2009 and assumed the Chair of the Board role in March 2020. Previously, she held several executive positions at Elevance Health, Inc., formerly WellPoint, Inc. from 1996 to 2007, including President, Specialty Products (which included behavioral health services); Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Prior to her time at WellPoint, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP (formerly Coopers & Lybrand, LLP), where she specialized in insurance. Her life science experience includes having previously served on the board of directors and Chair of the audit committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc. Ms. Phanstiel is currently a member of the board of directors of Butterfly Network, Inc. - S. Louise Phanstiel，自2021年2月业务合并完成后担任董事会成员，并担任审计委员会主席。Phanstiel女士自2020年3月起担任Myriad Genetics, Inc.（纳斯达克：MYGN）或Myriad的董事会主席，并自2009年9月起担任Myriad的董事。Phanstiel女士此前曾于1996年至2007年在Elevance Health, Inc.（NYSE：ELV）（前身为Anthem，Inc.，在此之前为WellPoint，Inc.）担任多个高管职务。Phanstiel女士曾任特种产品总裁，其中包括行为健康服务；董事长办公室高级副总裁、参谋长和企业规划；WellPoint，Inc.所有子公司的首席会计官、财务总监兼首席财务官。此前，Phanstiel女士是国际服务公司普华永道会计师事务所（PricewaterhouseCoopers，LLP）的合伙人。Phanstiel女士的生命科学经验包括曾在上市公司Inveresk Research Group，Inc.和Verastem Oncology（纳斯达克：VSTM）担任董事会成员和审计委员会主席。
- S. Louise Phanstiel has been a director of Myriad since September 2009 and assumed the Chair of the Board role in March 2020. Previously, she held several executive positions at Elevance Health, Inc., formerly WellPoint, Inc. from 1996 to 2007, including President, Specialty Products (which included behavioral health services); Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Prior to her time at WellPoint, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP (formerly Coopers & Lybrand, LLP), where she specialized in insurance. Her life science experience includes having previously served on the board of directors and Chair of the audit committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc. Ms. Phanstiel is currently a member of the board of directors of Butterfly Network, Inc.
- Paul M. Bisaro
-
Paul M. Bisaro，从2018年5月到2019年8月，他是Amneal Pharmaceuticals， Inc.（一家全球专业制药公司）的前执行主席。Amneal是由Amneal Pharmaceuticals LLC和Impax Laboratories， Inc.合并而成，Bisaro先生在2017年3月至2018年5月担任总裁兼首席执行官期间领导Impax Laboratories，在此期间，他负责监督所有营销和销售活动。2014年7月至2016年10月，Bisaro先生担任Allergan plc（前身为Actavis plc）的董事会执行主席，在那里他通过并购活动在公司发展中发挥了主导作用。直到2014年6月，Bisaro先生担任全球制药公司Actavis（原Watson Pharmaceuticals）的董事会主席、总裁兼首席执行官。他于2007年9月被任命为Watson的总裁、首席执行官和董事会成员，并于2013年10月被任命为董事会主席。加入Watson之前，他曾担任Barr Pharmaceuticals，Inc.（全球专业和仿制药制造商）的总裁、首席运营官和董事会成员，负责全球制造业务。从1992年到1999年，Bisaro先生担任Barr的总法律顾问，从1997年到1999年，他担任各种其他职务，包括战略业务发展高级副总裁。他在制药行业的各种法律和行政领导职位上拥有近30年的经验。除了在Zoetis董事会任职外，Bisaro先生还担任Mallinckrodt plc的董事会主席（自2024年2月起，之前从2022年6月至2023年11月）和Myriad Genetics， Inc.的董事会主席（自2022年10月起）。此前，他曾担任Allergan plc（及其前身公司）、Zimmer Biomet Holdings, Inc.、Amneal Pharmaceuticals（及其前身Impax）和TherapeuticsMD， Inc.的董事会成员。Bisaro先生拥有密歇根大学学士学位，以及华盛顿特区美国Catholic大学的法学博士学位。
Paul M. Bisaro,is the former Executive Chairman of Amneal Pharmaceuticals, Inc., a global specialty pharmaceutical company, from May 2018 to August 2019. Amneal was formed by the merger of Amneal Pharmaceuticals LLC and Impax Laboratories, Inc., which Mr. Bisaro led during his tenure as President and Chief Executive Officer from March 2017 to May 2018, during which he oversaw, among others, all marketing and sales activities. Mr. Bisaro was previously the Executive Chairman of the Board of Directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016, where he played a leading role in growing the company through M&A activity. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis (formerly Watson Pharmaceuticals), a global pharmaceutical company. He was appointed President, Chief Executive Officer and a member of the Board of Directors of Watson in September 2007 and was later appointed Board Chairman in October 2013. Prior to Watson, Mr. Bisaro was President, Chief Operating Officer and member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty and generic drug manufacturer where he was responsible for global manufacturing operations. Mr. Bisaro served as Barr's General Counsel from 1992 to 1999, and from 1997 to 1999 he served in various additional capacities including Senior Vice President—Strategic Business Development. Mr. Bisaro brings nearly 30 years of experience in various legal and executive leadership positions in the pharmaceutical industry.In addition to his service on the Zoetis Board, Mr. Bisaro serves as Chair of the Board of Mallinckrodt plc (since February 2024, and previously from June 2022 - November 2023) and on the Board of Directors of Myriad Genetics, Inc. (since October 2022). Mr. Bisaro previously served on the Boards of Directors of Allergan plc (and its predecessor companies), Zimmer Biomet Holdings, Inc., Amneal Pharmaceuticals (and its predecessor Impax) and TherapeuticsMD, Inc. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. - Paul M. Bisaro，从2018年5月到2019年8月，他是Amneal Pharmaceuticals， Inc.（一家全球专业制药公司）的前执行主席。Amneal是由Amneal Pharmaceuticals LLC和Impax Laboratories， Inc.合并而成，Bisaro先生在2017年3月至2018年5月担任总裁兼首席执行官期间领导Impax Laboratories，在此期间，他负责监督所有营销和销售活动。2014年7月至2016年10月，Bisaro先生担任Allergan plc（前身为Actavis plc）的董事会执行主席，在那里他通过并购活动在公司发展中发挥了主导作用。直到2014年6月，Bisaro先生担任全球制药公司Actavis（原Watson Pharmaceuticals）的董事会主席、总裁兼首席执行官。他于2007年9月被任命为Watson的总裁、首席执行官和董事会成员，并于2013年10月被任命为董事会主席。加入Watson之前，他曾担任Barr Pharmaceuticals，Inc.（全球专业和仿制药制造商）的总裁、首席运营官和董事会成员，负责全球制造业务。从1992年到1999年，Bisaro先生担任Barr的总法律顾问，从1997年到1999年，他担任各种其他职务，包括战略业务发展高级副总裁。他在制药行业的各种法律和行政领导职位上拥有近30年的经验。除了在Zoetis董事会任职外，Bisaro先生还担任Mallinckrodt plc的董事会主席（自2024年2月起，之前从2022年6月至2023年11月）和Myriad Genetics， Inc.的董事会主席（自2022年10月起）。此前，他曾担任Allergan plc（及其前身公司）、Zimmer Biomet Holdings, Inc.、Amneal Pharmaceuticals（及其前身Impax）和TherapeuticsMD， Inc.的董事会成员。Bisaro先生拥有密歇根大学学士学位，以及华盛顿特区美国Catholic大学的法学博士学位。
- Paul M. Bisaro,is the former Executive Chairman of Amneal Pharmaceuticals, Inc., a global specialty pharmaceutical company, from May 2018 to August 2019. Amneal was formed by the merger of Amneal Pharmaceuticals LLC and Impax Laboratories, Inc., which Mr. Bisaro led during his tenure as President and Chief Executive Officer from March 2017 to May 2018, during which he oversaw, among others, all marketing and sales activities. Mr. Bisaro was previously the Executive Chairman of the Board of Directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016, where he played a leading role in growing the company through M&A activity. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis (formerly Watson Pharmaceuticals), a global pharmaceutical company. He was appointed President, Chief Executive Officer and a member of the Board of Directors of Watson in September 2007 and was later appointed Board Chairman in October 2013. Prior to Watson, Mr. Bisaro was President, Chief Operating Officer and member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty and generic drug manufacturer where he was responsible for global manufacturing operations. Mr. Bisaro served as Barr's General Counsel from 1992 to 1999, and from 1997 to 1999 he served in various additional capacities including Senior Vice President—Strategic Business Development. Mr. Bisaro brings nearly 30 years of experience in various legal and executive leadership positions in the pharmaceutical industry.In addition to his service on the Zoetis Board, Mr. Bisaro serves as Chair of the Board of Mallinckrodt plc (since February 2024, and previously from June 2022 - November 2023) and on the Board of Directors of Myriad Genetics, Inc. (since October 2022). Mr. Bisaro previously served on the Boards of Directors of Allergan plc (and its predecessor companies), Zimmer Biomet Holdings, Inc., Amneal Pharmaceuticals (and its predecessor Impax) and TherapeuticsMD, Inc. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C.
高管简历
中英对照 | 中文 | 英文- Mark Verratti
Mark Verratti，Myriad Neuroscience and Myriad AutoImmune.的总裁，自2017年8月1日起担任现任职务。他此前曾担任Assurex公司的高级副总裁、首席销售和业务开发官（2016年1月以来）。他也曾担任Cyberonics公司（现称为Livanova公司）的高级领导职务（2005年至2016年），此前曾任职Forest Pharmaceuticals公司，在那里他曾领导商业团队，其收入接近5亿美元。他在宾夕法尼亚州立大学（Pennsylvania State University）获得生命科学学士学位，辅修生理学。
Mark Verratti has served as Chief Operating Officer since April 30, 2025. Previously, he served as Chief Commercial Officer from April 2022 to April 2025. Since joining Myriad, Mr. Verratti has held several key leadership positions, including President, Mental Health or President (Myriad Neuroscience) from August 2017 to April 2022, and as President of Myriad Autoimmune from May 2020 until the divestiture of that business in September 2021. Prior to his appointment as President of Myriad Neuroscience, he served as Senior Vice President and Chief Sales and Business Development Officer at Assurex Health beginning in January 2016. Mr. Verratti also held senior leadership positions worldwide with Cyberonics (now known as LivaNova) from 2005 to 2016, and earlier with Forest Pharmaceuticals, where he led commercial teams with revenues approaching $500 million dollars. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.- Mark Verratti，Myriad Neuroscience and Myriad AutoImmune.的总裁，自2017年8月1日起担任现任职务。他此前曾担任Assurex公司的高级副总裁、首席销售和业务开发官（2016年1月以来）。他也曾担任Cyberonics公司（现称为Livanova公司）的高级领导职务（2005年至2016年），此前曾任职Forest Pharmaceuticals公司，在那里他曾领导商业团队，其收入接近5亿美元。他在宾夕法尼亚州立大学（Pennsylvania State University）获得生命科学学士学位，辅修生理学。
- Mark Verratti has served as Chief Operating Officer since April 30, 2025. Previously, he served as Chief Commercial Officer from April 2022 to April 2025. Since joining Myriad, Mr. Verratti has held several key leadership positions, including President, Mental Health or President (Myriad Neuroscience) from August 2017 to April 2022, and as President of Myriad Autoimmune from May 2020 until the divestiture of that business in September 2021. Prior to his appointment as President of Myriad Neuroscience, he served as Senior Vice President and Chief Sales and Business Development Officer at Assurex Health beginning in January 2016. Mr. Verratti also held senior leadership positions worldwide with Cyberonics (now known as LivaNova) from 2005 to 2016, and earlier with Forest Pharmaceuticals, where he led commercial teams with revenues approaching $500 million dollars. He received a B.S. in Life Sciences with a minor in Physiology from The Pennsylvania State University.
- Samraat S. Raha
Samraat S. Raha自2018年4月起担任安捷伦高级副总裁兼诊断与基因组学总裁。从2017年5月至2018年4月，Raha先生担任战略与企业发展高级副总裁。 2013年6月至2017年1月，他担任Illumina公司全球营销副总裁，并于2008年至2012年担任Life Technologies Assays / NextGen qPCR for Life Technologies，Inc的副总裁兼总经理。
Samraat S. Raha has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Diagnostics and Genomics Group since April 2018. From May 2017 to April 2018, Mr. Raha served as Agilent Technologies, Inc. Senior Vice President, Strategy and Corporate Development. From June 2013 to January 2017 he served as Vice President, Global Marketing for Illumina, Inc. and from 2008 to 2012 he served as Vice President and General Manager, Genomic Assays / NextGen qPCR for Life Technologies, Inc. Mr. Raha graduated from the University of California, Berkeley, with a degree in molecular and cell biology and received his MBA from Santa Clara University.- Samraat S. Raha自2018年4月起担任安捷伦高级副总裁兼诊断与基因组学总裁。从2017年5月至2018年4月，Raha先生担任战略与企业发展高级副总裁。 2013年6月至2017年1月，他担任Illumina公司全球营销副总裁，并于2008年至2012年担任Life Technologies Assays / NextGen qPCR for Life Technologies，Inc的副总裁兼总经理。
- Samraat S. Raha has served as Agilent Technologies, Inc. Senior Vice President, Agilent and President, Diagnostics and Genomics Group since April 2018. From May 2017 to April 2018, Mr. Raha served as Agilent Technologies, Inc. Senior Vice President, Strategy and Corporate Development. From June 2013 to January 2017 he served as Vice President, Global Marketing for Illumina, Inc. and from 2008 to 2012 he served as Vice President and General Manager, Genomic Assays / NextGen qPCR for Life Technologies, Inc. Mr. Raha graduated from the University of California, Berkeley, with a degree in molecular and cell biology and received his MBA from Santa Clara University.
- Ben R. Wheeler
Ben R. Wheeler，在过去十三年中曾在公司担任过各种职责不断增加的职务，包括最近自2022年6月起担任高级副总裁、运营首席财务官，自2020年7月起担任财务和财务高级副总裁。Wheeler先生还曾于2018年6月至2020年7月在公司担任高级副总裁，会计，副总裁，公司财务总监，2014年12月至2018年6月，并于2011年12月至2014年12月担任其他控制职位。在加入公司之前，Wheeler先生曾担任安永会计师事务所的审计师。Wheeler先生拥有杨百翰大学会计学硕士和学士学位，是一名注册会计师。
Ben R. Wheeler has served as Chief Financial Officer since August 16, 2025. Since joining Myriad in December 2011, Mr. Wheeler has held several positions of increasing responsibility within the finance organization, including Senior Vice President, Chief Financial Officer, Operations from June 2022 to August 2025; Senior Vice President of Finance & Treasury from July 2020 to June 2022; and Senior Vice President, Accounting from June 2018 to July 2020. Previously, he served as Vice President, Corporate Controller from December 2014 to June 2018, and as Division Controller from December 2011 to December 2014. Mr. Wheeler holds a Bachelor of Science and a Master of Accounting (MAcc) from Brigham Young University.- Ben R. Wheeler，在过去十三年中曾在公司担任过各种职责不断增加的职务，包括最近自2022年6月起担任高级副总裁、运营首席财务官，自2020年7月起担任财务和财务高级副总裁。Wheeler先生还曾于2018年6月至2020年7月在公司担任高级副总裁，会计，副总裁，公司财务总监，2014年12月至2018年6月，并于2011年12月至2014年12月担任其他控制职位。在加入公司之前，Wheeler先生曾担任安永会计师事务所的审计师。Wheeler先生拥有杨百翰大学会计学硕士和学士学位，是一名注册会计师。
- Ben R. Wheeler has served as Chief Financial Officer since August 16, 2025. Since joining Myriad in December 2011, Mr. Wheeler has held several positions of increasing responsibility within the finance organization, including Senior Vice President, Chief Financial Officer, Operations from June 2022 to August 2025; Senior Vice President of Finance & Treasury from July 2020 to June 2022; and Senior Vice President, Accounting from June 2018 to July 2020. Previously, he served as Vice President, Corporate Controller from December 2014 to June 2018, and as Division Controller from December 2011 to December 2014. Mr. Wheeler holds a Bachelor of Science and a Master of Accounting (MAcc) from Brigham Young University.
- Jennifer Fox
自2024年9月加入Myriad以来，詹妮弗·福克斯一直担任首席法务官。在加入公司之前，她曾于2022年3月至2024年8月担任Emergent BioSolutions Inc.（Emergent）的执行副总裁、对外事务、总法律顾问和公司秘书，负责监督法律职能、政府和公共事务、沟通和ESG举措。在担任该职务之前，她曾于2020年1月至2022年2月担任高级副总裁、法律事务、副总法律顾问，并于2018年12月至2019年12月在Emergent担任副总裁、副总法律顾问。在加入Emergent之前，Fox女士是Brinks，Gilson & Lione律师事务所的律师和股东，此前曾担任诺维信和GSK的内部律师。在从事法律职业之前，她曾在美国国立卫生研究院和GSK担任研究科学家。福克斯女士获得了北卡罗来纳中央大学的法学博士学位、分子生物学和生物化学硕士学位，以及托莱多大学的生物学学士学位。
Jennifer Fox has served as Chief Legal Officer since joining Myriad in September 2024. Prior to joining the Company, she served as the Executive Vice President, External Affairs, General Counsel and Corporate Secretary of Emergent BioSolutions Inc. (Emergent) from March 2022 to August 2024, where she was responsible for overseeing legal functions, government and public affairs, communications, and ESG initiatives. Prior to that role, she served as Senior Vice President, Legal Affairs, Deputy General Counsel from January 2020 to February 2022, and as Vice President, Associate General Counsel from December 2018 to December 2019 at Emergent. Before joining Emergent, Ms. Fox was an attorney and shareholder at the law firm of Brinks, Gilson & Lione, and previously served as an in house attorney for Novozymes and GSK. Prior to her legal career, she worked as a research scientist at the National Institutes of Health and GSK. Ms. Fox received her J.D. from North Carolina Central University, an M.S. in molecular biology and biochemistry, and a B.S. in Biology from the University of Toledo.- 自2024年9月加入Myriad以来，詹妮弗·福克斯一直担任首席法务官。在加入公司之前，她曾于2022年3月至2024年8月担任Emergent BioSolutions Inc.（Emergent）的执行副总裁、对外事务、总法律顾问和公司秘书，负责监督法律职能、政府和公共事务、沟通和ESG举措。在担任该职务之前，她曾于2020年1月至2022年2月担任高级副总裁、法律事务、副总法律顾问，并于2018年12月至2019年12月在Emergent担任副总裁、副总法律顾问。在加入Emergent之前，Fox女士是Brinks，Gilson & Lione律师事务所的律师和股东，此前曾担任诺维信和GSK的内部律师。在从事法律职业之前，她曾在美国国立卫生研究院和GSK担任研究科学家。福克斯女士获得了北卡罗来纳中央大学的法学博士学位、分子生物学和生物化学硕士学位，以及托莱多大学的生物学学士学位。
- Jennifer Fox has served as Chief Legal Officer since joining Myriad in September 2024. Prior to joining the Company, she served as the Executive Vice President, External Affairs, General Counsel and Corporate Secretary of Emergent BioSolutions Inc. (Emergent) from March 2022 to August 2024, where she was responsible for overseeing legal functions, government and public affairs, communications, and ESG initiatives. Prior to that role, she served as Senior Vice President, Legal Affairs, Deputy General Counsel from January 2020 to February 2022, and as Vice President, Associate General Counsel from December 2018 to December 2019 at Emergent. Before joining Emergent, Ms. Fox was an attorney and shareholder at the law firm of Brinks, Gilson & Lione, and previously served as an in house attorney for Novozymes and GSK. Prior to her legal career, she worked as a research scientist at the National Institutes of Health and GSK. Ms. Fox received her J.D. from North Carolina Central University, an M.S. in molecular biology and biochemistry, and a B.S. in Biology from the University of Toledo.
- Dale Muzzey
Dale Muzzey自2022年4月起担任首席科学官。此前，他曾于2022年1月至2022年4月在Myriad担任临时首席科学官和高级副总裁，研发；2019年10月至2021年12月担任生物信息学副总裁；2018年8月至2019年9月担任临床开发高级总监。从2014年4月到2018年7月，Muzzey博士还在Myriad Women's Health担任过多个责任越来越大的职位，包括科学事务总监、工作人员科学家、计算生物学、高级科学家和计算科学家I。Muzzey博士获得了哈佛大学生化科学文学学士学位和生物物理学博士学位。
Dale Muzzey has served as Chief Scientific Officer since April 2022. Previously, he served at Myriad as Interim Chief Scientific Officer and Senior Vice President, R&D from January 2022 to April 2022; Vice President, Bioinformatics, from October 2019 to December 2021; and Senior Director, Clinical Development from August 2018 to September 2019. From April 2014 to July 2018, Dr. Muzzey also served in a number of positions of increasing responsibility at Myriad Women's Health, including Director, Scientific Affairs, Staff Scientist, Computational Biology, Senior Scientist, and Computational Scientist I. Dr. Muzzey received a Bachelor of Arts degree in Biochemical Sciences and a Ph.D. in Biophysics from Harvard University.- Dale Muzzey自2022年4月起担任首席科学官。此前，他曾于2022年1月至2022年4月在Myriad担任临时首席科学官和高级副总裁，研发；2019年10月至2021年12月担任生物信息学副总裁；2018年8月至2019年9月担任临床开发高级总监。从2014年4月到2018年7月，Muzzey博士还在Myriad Women's Health担任过多个责任越来越大的职位，包括科学事务总监、工作人员科学家、计算生物学、高级科学家和计算科学家I。Muzzey博士获得了哈佛大学生化科学文学学士学位和生物物理学博士学位。
- Dale Muzzey has served as Chief Scientific Officer since April 2022. Previously, he served at Myriad as Interim Chief Scientific Officer and Senior Vice President, R&D from January 2022 to April 2022; Vice President, Bioinformatics, from October 2019 to December 2021; and Senior Director, Clinical Development from August 2018 to September 2019. From April 2014 to July 2018, Dr. Muzzey also served in a number of positions of increasing responsibility at Myriad Women's Health, including Director, Scientific Affairs, Staff Scientist, Computational Biology, Senior Scientist, and Computational Scientist I. Dr. Muzzey received a Bachelor of Arts degree in Biochemical Sciences and a Ph.D. in Biophysics from Harvard University.
- Brian Donnelly
自2025年5月加入Myriad以来，Brian Donnelly一直担任首席商务官。在加入公司之前，唐纳利先生于2021年7月至2025年4月担任Ancestry的首席商务官，领导全球商业运营，包括营销、业务发展以及国际和新兴业务，包括AncestryDNA。此前，他于2020年7月至2021年7月在亚马逊担任全球领导者、诊断与基因组学，并于2019年12月至2020年7月担任Codex DNA（现为Telesis Bio）的首席商务官。唐纳利先生拥有埃隆大学工商管理理学学士学位，以及罗格斯大学工商管理硕士和法学博士学位。
Brian Donnelly has served as Chief Commercial Officer since joining Myriad in May 2025. Prior to joining the Company, Mr. Donnelly served as Chief Commercial Officer at Ancestry from July 2021 to April 2025, where he led global commercial operations, including marketing, business development, and international and emerging businesses, including AncestryDNA. Previously, he served as Worldwide Leader, Diagnostics & Genomics at Amazon from July 2020 to July 2021 and as Chief Commercial Officer of Codex DNA (now Telesis Bio) from December 2019 to July 2020. Mr. Donnelly holds a Bachelor of Science in Business Administration from Elon University, as well as a Master of Business Administration and a J.D. from Rutgers University.- 自2025年5月加入Myriad以来，Brian Donnelly一直担任首席商务官。在加入公司之前，唐纳利先生于2021年7月至2025年4月担任Ancestry的首席商务官，领导全球商业运营，包括营销、业务发展以及国际和新兴业务，包括AncestryDNA。此前，他于2020年7月至2021年7月在亚马逊担任全球领导者、诊断与基因组学，并于2019年12月至2020年7月担任Codex DNA（现为Telesis Bio）的首席商务官。唐纳利先生拥有埃隆大学工商管理理学学士学位，以及罗格斯大学工商管理硕士和法学博士学位。
- Brian Donnelly has served as Chief Commercial Officer since joining Myriad in May 2025. Prior to joining the Company, Mr. Donnelly served as Chief Commercial Officer at Ancestry from July 2021 to April 2025, where he led global commercial operations, including marketing, business development, and international and emerging businesses, including AncestryDNA. Previously, he served as Worldwide Leader, Diagnostics & Genomics at Amazon from July 2020 to July 2021 and as Chief Commercial Officer of Codex DNA (now Telesis Bio) from December 2019 to July 2020. Mr. Donnelly holds a Bachelor of Science in Business Administration from Elon University, as well as a Master of Business Administration and a J.D. from Rutgers University.
- Shereen Solaiman
Shereen Solaiman自2009年8月起担任公司人力资源高级副总裁。Solaiman从2009年2月到2009年8月担任人力资源副总裁；2007年8月到2009年2月担任Corporate, D.C。 和 Field Human Resources副总裁。在此之前，Solaiman从2003年12月到2007年8月担任企业人力资源主管。Solaiman持有Ohio University新闻理学学士学位，主修公共关系；New York University公共管理硕士学位，主修管理。
Shereen Solaiman has served as Senior Vice President, Human Resources for the Company since August 2009. Ms. Solaiman served as Vice President, Human Resources from February 2009 until August 2009 and Vice President, Corporate, D.C. and Field Human Resources from August 2007 until February 2009. Prior to that Ms. Solaiman served as Director, Corporate Human Resources from December 2003 until August 2007. Ms. Solaiman has a bachelor of science in journalism with a major in public relations from Ohio University and a masters in public administration with a specialization in management from New York University.- Shereen Solaiman自2009年8月起担任公司人力资源高级副总裁。Solaiman从2009年2月到2009年8月担任人力资源副总裁；2007年8月到2009年2月担任Corporate, D.C。 和 Field Human Resources副总裁。在此之前，Solaiman从2003年12月到2007年8月担任企业人力资源主管。Solaiman持有Ohio University新闻理学学士学位，主修公共关系；New York University公共管理硕士学位，主修管理。
- Shereen Solaiman has served as Senior Vice President, Human Resources for the Company since August 2009. Ms. Solaiman served as Vice President, Human Resources from February 2009 until August 2009 and Vice President, Corporate, D.C. and Field Human Resources from August 2007 until February 2009. Prior to that Ms. Solaiman served as Director, Corporate Human Resources from December 2003 until August 2007. Ms. Solaiman has a bachelor of science in journalism with a major in public relations from Ohio University and a masters in public administration with a specialization in management from New York University.